

NCT03190304 comparison:

Summary:
CHIA has 25 criteria while your personal folder has 25 criteria
Total found criteria: 25/25
Total not Found: 0/25
Total Extra: 1
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Symptomatic patients with heart failure (men and   │ Symptomatic patients with heart failure (men and   │
│ women) aged >18 years                              │ women) aged \>18 years                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Functional class II, III or IV by the New York     │ Functional class II, III or IV by the New York     │
│ Heart Association (NYHA)                           │ Heart Association (NYHA)                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Left ventricular ejection fraction <35%            │ Left ventricular ejection fraction \<35%           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ischemic and nonischemic etiology                  │ Ischemic and nonischemic etiology                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Type B natriuretic peptide (BNP) >150 pg/ml (or    │ Type B natriuretic peptide (BNP) \>150 pg/ml (or   │
│ pro-BNP [N-terminal-proBNP] = 600 pg / ml) or if   │ pro-BNP \[N-terminal-proBNP\] ≥ 600 pg / ml) or if │
│ the patient was hospitalized for cardiac           │ the patient was hospitalized for cardiac           │
│ decompensation within the preceding 12 months, BNP │ decompensation within the preceding 12 months, BNP │
│ >100 pg/ml (or N-terminal-proBNP = 400 pg / ml)    │ \>100 pg/ml (or N-terminal-proBNP ≥ 400 pg / ml)   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of hypersensitivity or allergy to any of   │ History of hypersensitivity or allergy to any of   │
│ the study drugs, drugs of similar chemical         │ the study drugs, drugs of similar chemical         │
│ classes, ACE inhibitors (ACEIs), angiotensin II    │ classes, ACE inhibitors (ACEIs), angiotensin II    │
│ receptor blockers (ARBs), or neprilysin            │ receptor blockers (ARBs), or neprilysin            │
│ inhibitors, as well as known or suspected          │ inhibitors, as well as known or suspected          │
│ contraindications to the study drugs               │ contraindications to the study drugs               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previous history of intolerance to recommended     │ Previous history of intolerance to recommended     │
│ target doses of ACEIs or ARBs                      │ target doses of ACEIs or ARBs                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known history of angioedema                        │ Known history of angioedema                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Requirement for treatment with both ACEIs and ARBs │ Requirement for treatment with both ACEIs and ARBs │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current acute decompensated heart failure          │ Current acute decompensated heart failure          │
│ (exacerbation of chronic heart failure manifested  │ (exacerbation of chronic heart failure manifested  │
│ by signs and symptoms that may require intravenous │ by signs and symptoms that may require intravenous │
│ therapy)                                           │ therapy)                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Symptomatic hypotension                            │ Symptomatic hypotension                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Estimated glomerular filtration rate (eGFR) <30%   │ Estimated glomerular filtration rate (eGFR) \<30%  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum potassium >5.4 mmol/L                        │ Serum potassium \>5.4 mmol/L                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Acute coronary syndrome, stroke, transient         │ Acute coronary syndrome, stroke, transient         │
│ ischaemic attack, cardiac, carotid, or other major │ ischaemic attack, cardiac, carotid, or other major │
│ cardiovascular surgery, percutaneous coronary      │ cardiovascular surgery, percutaneous coronary      │
│ intervention, or carotid angioplasty within the 3  │ intervention, or carotid angioplasty within the 3  │
│ months                                             │ months                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Coronary or carotid artery disease likely to       │ Coronary or carotid artery disease likely to       │
│ require surgical or percutaneous intervention      │ require surgical or percutaneous intervention      │
│ within the 6 months                                │ within the 6 months                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Implantation of a cardiac resynchronization        │ Implantation of a cardiac resynchronization        │
│ therapy (CRT) device within 3 months or intent to  │ therapy (CRT) device within 3 months or intent to  │
│ implant a CRT                                      │ implant a CRT                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of heart transplant or on a transplant     │ History of heart transplant or on a transplant     │
│ list or with left ventricular (LV) assistance      │ list or with left ventricular (LV) assistance      │
│ device                                             │ device                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of severe pulmonary disease                │ History of severe pulmonary disease                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Diagnosis of peripartum- or chemotherapy-induced   │ Diagnosis of peripartum- or chemotherapy-induced   │
│ cardiomyopathy within the 12 months                │ cardiomyopathy within the 12 months                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Documented untreated ventricular arrhythmia with   │ Documented untreated ventricular arrhythmia with   │
│ syncopal episodes within the 3 months              │ syncopal episodes within the 3 months              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Symptomatic bradycardia or second- or third-degree │ Symptomatic bradycardia or second- or third-degree │
│ atrioventricular block without a pacemaker         │ atrioventricular block without a pacemaker         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Presence of haemodynamically significant mitral    │ Presence of haemodynamically significant mitral    │
│ and/or aortic valve disease, except mitral         │ and/or aortic valve disease, except mitral         │
│ regurgitation secondary to LV dilatation           │ regurgitation secondary to LV dilatation           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Presence of other haemodynamically significant     │ Presence of other haemodynamically significant     │
│ obstructive lesions of the LV outflow tract,       │ obstructive lesions of the LV outflow tract,       │
│ including aortic and subaortic stenosis            │ including aortic and subaortic stenosis            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any surgical or medical condition which might      │ Any surgical or medical condition which might      │
│ significantly alter the absorption, distribution,  │ significantly alter the absorption, distribution,  │
│ metabolism, or excretion of study drugs,           │ metabolism, or excretion of study drugs,           │
│ including, but not limited to, any of the          │ including, but not limited to, any of the          │
│ following: History of active inflammatory bowel    │ following: History of active inflammatory bowel    │
│ disease during the 12 months. Active duodenal or   │ disease during the 12 months. Active duodenal or   │
│ gastric ulcers during the 3 months. Evidence of    │ gastric ulcers during the 3 months. Evidence of    │
│ hepatic disease as determined by any one of the    │ hepatic disease as determined by any one of the    │
│ following: aspartate aminotransferase or alanine   │ following: aspartate aminotransferase or alanine   │
│ aminotransferase values exceeding 2x upper limit   │ aminotransferase values exceeding 2x upper limit   │
│ of normal, history of hepatic encephalopathy,      │ of normal, history of hepatic encephalopathy,      │
│ history of oesophageal varices, or history of      │ history of oesophageal varices, or history of      │
│ porto-caval shunt. Current treatment with          │ porto-caval shunt. Current treatment with          │
│ cholestyramine or colestipol resins                │ cholestyramine or colestipol resins                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Presence of any other disease with a life          │ Presence of any other disease with a life          │
│ expectancy of <5 years                             │ expectancy of \<5 years                            │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛